Glecaprevir

Category: pharmacological

Aliases: Component of Mavyret

Pharmacological Mechanism

Pan-genotypic HCV NS3/4A protease inhibitor — blocks viral polyprotein cleavage. Co-formulated with the NS5A inhibitor pibrentasvir as Mavyret for 8-week pan-genotypic HCV cure regimen.

Half-Life (t½)

PO: 6h

Dosing Guidelines

• PO: Typical 300mg (Range: 300 - 300 mg)

Target Organ Systems

• immune-hematologic